Biomm S.A (SA:BIOM3) — Market Cap & Net Worth
Market Cap & Net Worth: Biomm S.A (BIOM3)
Biomm S.A (SA:BIOM3) has a market capitalization of $172.92 Million (R$881.26 Million) as of October 6, 2026. Listed on the SA stock exchange, this Brazil-based company holds position #17169 globally and #165 in its home market, demonstrating a 5.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomm S.A's stock price R$6.44 by its total outstanding shares 136841532 (136.84 Million).
Biomm S.A Market Cap History: 2015 to 2026
Biomm S.A's market capitalization history from 2015 to 2026. Data shows change from $150.36 Million to $172.92 Million (-0.22% CAGR). Check BIOM3 share price today for real-time trading data and today's change.
Biomm S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biomm S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see BIOM3 cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
2.00x
Biomm S.A's market cap is 2.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $255.08 Million | $103.00K | -$38.13 Million | 2476.53x | N/A |
| 2018 | $219.37 Million | $1.57 Million | -$42.56 Million | 140.08x | N/A |
| 2019 | $332.95 Million | $8.94 Million | -$55.81 Million | 37.23x | N/A |
| 2020 | $435.25 Million | $58.67 Million | -$70.77 Million | 7.42x | N/A |
| 2021 | $348.52 Million | $107.09 Million | -$80.26 Million | 3.25x | N/A |
| 2022 | $182.32 Million | $104.95 Million | -$92.56 Million | 1.74x | N/A |
| 2023 | $155.20 Million | $118.19 Million | -$81.14 Million | 1.31x | N/A |
| 2024 | $286.23 Million | $142.91 Million | -$77.24 Million | 2.00x | N/A |
Competitor Companies of BIOM3 by Market Capitalization
Companies near Biomm S.A in the global market cap rankings as of October 6, 2026. See BIOM3 equity to assets ratio to understand what proportion of total assets are financed by equity.
Key companies related to Biomm S.A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.62 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #379 globally with a market cap of $73.47 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.76 Billion USD ( AU$85.87 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.62 Billion | $503.50 |
| #379 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.47 Billion | $726.47 |
| #455 | CSL Ltd | AU:CSL | $60.76 Billion | AU$176.99 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $203.21 |
Biomm S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, Biomm S.A's market cap moved from $150.36 Million to $ 172.92 Million, with a yearly change of -0.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | R$172.92 Million | -10.80% |
| 2025 | R$193.86 Million | -32.27% |
| 2024 | R$286.23 Million | +84.43% |
| 2023 | R$155.20 Million | -14.87% |
| 2022 | R$182.32 Million | -47.69% |
| 2021 | R$348.52 Million | -19.93% |
| 2020 | R$435.25 Million | +30.73% |
| 2019 | R$332.95 Million | +51.77% |
| 2018 | R$219.37 Million | -14.00% |
| 2017 | R$255.08 Million | +47.29% |
| 2016 | R$173.19 Million | +15.18% |
| 2015 | R$150.36 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 6th, 2026 the market cap of Biomm S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $172.92 Million USD |
| MoneyControl | $172.92 Million USD |
| MarketWatch | $172.92 Million USD |
| marketcap.company | $172.92 Million USD |
| Reuters | $172.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more